AMS for Carbon-14 Non-clinical Studies
AMS for Carbon-14 Non-clinical Studies Services
The utilization of Accelerator Mass Spectrometry (AMS) in non-clinical studies is less common as high doses of 14C radioactivity in animal models are generally not restricted by radiological safety concerns. AMS-enabled non-clinical applications typically focus on potent compounds where doses in animal models are correspondingly low, requiring the ultra-sensitivity for 14C analysis that AMS provides. By partnering with Pharmaron, we employ state-of-the-art AMS to generate the quantitative and qualitative data that helps to advance your development programs.
AMS facilitates accurate quantitation of total [14C] and 14C-parent/metabolite(s) in a wide range of sample types (blood, plasma, excreta, tissues, cells, biological fluids). The sensitivity of AMS analysis only requires very small (mg/µg) sample sizes. We also employ AMS in conjunction with HPLC/UPLC fractionation methods for metabolite profiling in all biological matrices.
Radioanalysis can be integrated with Pharmaron’s radiosynthesis capabilities for radiolabelling both small and large molecules with 14C.
Preclinical Toxicology and Metabolism
- Toxicokinetics – Bioanalysis of [14C]-parent compound
- Mass balance/metabolite profiling
Target Turnover Studies
- Assess “drugability” of therapeutic targets in preclinical models
- 14C radiolabelled proteins and cytokines
- Targeting of tumor tissues in disease models
LC+AMS Bioanalysis and Total [14C] by AMS for Potent Molecules
- Fusion proteins
Analysis of [14C]-Parent/ Metabolite(s) in a Wide Range of Biological Matrices
- Expired air
- Biopsy tissue
- Cells e.g PBMCs